KPV: how it works, research and approval status

Whether KPV helps with intestinal inflammation or skin problems has not yet been established in humans. Indications of anti-inflammatory effects come from cell and animal studies. Controlled human trials are lacking.

What is KPV?

KPV is a tripeptide, a compound of three amino acids: lysine, proline and valine. This sequence forms the terminal segment of alpha-MSH, a hormone with anti-inflammatory properties.

Wellness providers and sellers of “research peptides” market KPV for intestinal inflammation, including inflammatory bowel disease, and for use on the skin. A benefit for these uses has not been demonstrated in humans. KPV is not an approved medicine.

How does KPV work?

In laboratory models, KPV shows much of alpha-MSH’s anti-inflammatory activity. Intestinal and immune cells take up the peptide. Inside them, it is proposed to dampen inflammation-promoting signals, including the NF-κB pathway and the subsequent release of inflammatory messengers such as TNF-alpha. Part of the effect appears independent of the MC1R receptor, a binding site for signaling molecules.

This proposed mechanism is based on cell and animal experiments. It does not establish whether KPV also relieves inflammation in humans.

Is KPV FDA-approved?

No. The US Food and Drug Administration has not approved KPV.

Compounding means preparing a medicine for an individual patient; it is separate from FDA drug approval. On October 30, 2026, HHS announced a draft, nonbinding policy describing conditional enforcement discretion for specified single-ingredient peptides while final Section 503A bulk-list rulemaking continues. Its scope includes KPV acetate for oral and topical use, not injections. Conditions include a patient-specific prescription, verified identity, a qualifying manufacturer and certificate of analysis, testing, labeling, reporting of serious adverse events and quality problems, and other applicable requirements. For oral preparations, the policy also expects documentation that the particular formulation achieves adequate bioavailability in humans. It does not cover peptide blends, confer FDA approval, or establish that any particular seller complies. A clinician and pharmacist should check the current federal and state requirements for a specific preparation. HHS policy Federal Register

What does the research show?

KPV has so far been investigated in preclinical studies: cell and animal models before clinical testing in humans. Two studies indexed in PubMed examined mice with colitis, inflammation of the colon:

Form studied	Model	Result
KPV	Mouse models of colitis	Reduced inflammation, partly independently of MC1R (1)
KPV delivered using nanoparticles	Mice with colitis	Alleviated colitis; mucosal healing and reduced TNF-alpha were observed (2)

A review explains the basis of the anti-inflammatory activity (3). However, results from mouse models do not establish a benefit in humans. Controlled trials showing whether KPV helps with gut or skin problems are lacking. The marketed uses therefore extend beyond what has been demonstrated in humans so far.